In breast cancer, targeting BCSCs has been shown to be an effective treatment approach as evidenced in HER2+ BC, where combination therapy targeting the IL6 receptor and HER2 effectively abrogated tumor growth and metastasis by eliminating BCSCs 41. This evidence concerns the gene ERBB2 and breast carcinoma.